$19.85
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Overview
52-week range
$6.57
$28
62% of range
Avg surprise (last 3)
-13.2%
Avg reaction (last 2)
-2.5%
0% positive
Latest IV / EM
98%
EM ±22.4% · $20 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.57 | $-0.52 | -9.6% | -533.3% | -3.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.48 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.86 | $-0.43 | -100.0% | — | — | earnings |
| Fri Apr 25, 2025 | Mar/2025 | $-0.09 | $-0.30 | +70.0% | — | -1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-5.16 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.86 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.83 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.71 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.76 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.66 | -$0.86 | +23.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-43M | — | $-27M | $-28M | $-23M | — | $-15M | $-26M |
| Net income | $-40M | — | $-25M | $-32M | $-38M | — | $-16M | $-25M |
| EPS (diluted) | $-0.57 | — | $-0.48 | $-0.86 | $-12.10 | — | $-5.16 | $-0.86 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $55M | $88M | $50M | $221M | $44M | $69M | $31M | $31M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $319M | $349M | $201M | $223M | $77M | $70M | $91M | $111M |
| Total assets | $319M | $350M | $202M | $224M | $78M | $73M | $91M | $112M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $23M | $17M | $23M | $22M | $2M | $120M | $10M | $17M |
| Total equity | $296M | $333M | $179M | $202M | $-84M | $-47M | $-17M | $-589,000 |